Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Cell Pediatr. 2016 Dec;3(1):6. doi: 10.1186/s40348-016-0034-x. Epub 2016 Feb 11.

Mesenchymal stem/stromal cells-a key mediator for regeneration after perinatal morbidity?

Author information

1
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA. martin.mueller@insel.ch.
2
Department of Obstetrics and Gynecology, University Hospital Bern and Department of Clinical Research, University of Bern, Bern, Switzerland. martin.mueller@insel.ch.
3
Department of Pediatrics, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands. tim.wolfs@maastrichtuniversity.nl.
4
School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands. tim.wolfs@maastrichtuniversity.nl.
5
Department of Obstetrics and Gynecology, University Hospital Bern and Department of Clinical Research, University of Bern, Bern, Switzerland. andreina.schoeberlein@dkf.unibe.ch.
6
Department of Pediatrics, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands. danilo.gavilanes@mumc.nl.
7
Institute of Biomedicine, Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador. danilo.gavilanes@mumc.nl.
8
Department of Neuropsychology, Division Neuroscience, School of Mental Health and neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands. danilo.gavilanes@mumc.nl.
9
Department of Obstetrics and Gynecology, University Hospital Bern and Department of Clinical Research, University of Bern, Bern, Switzerland. daniel.surbek@insel.ch.
10
Department of Pediatrics, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands. b.kramer@maastrichtuniversity.nl.
11
School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands. b.kramer@maastrichtuniversity.nl.
12
Department of Neuropsychology, Division Neuroscience, School of Mental Health and neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands. b.kramer@maastrichtuniversity.nl.

Abstract

Perinatal complications in both term- and preterm-born infants are a leading cause of neonatal morbidities and mortality. Infants face different challenges in the neonatal intensive care unit with long-term morbidities such as perinatal brain injury and bronchopulmonary dysplasia being particularly devastating. While advances in perinatal medicine have improved our understanding of the pathogenesis, effective therapies to prevent and/or reduce the severity of these disorders are still lacking. The potential of mesenchymal stem/stromal cell (MSC) therapy has emerged during the last two decades, and an increasing effort is conducted to address brain- and lung-related morbidities in neonates at risk. Various studies support the notion that MSCs have protective effects. MSCs are an easy source and may be readily available after birth in a clinical setting. MSCs' mechanisms of action are diverse, including migration and homing, release of growth factors and immunomodulation, and the potential to replace injured cells. Here, we review the pathophysiology of perinatally acquired brain and lung injuries and focus on MSCs as potential candidates for therapeutic strategies summarizing preclinical and clinical evidence.

KEYWORDS:

Bronchopulmonary dysplasia; Hypoxic-ischemic encephalopathy; Mesenchymal stem cells; Neonatal; Perinatal; Perinatal brain injury

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center